非布索坦国内上市没？

It is a tablet and is an anti-gout medicine. Febuxostat has a significant inhibitory effect on both oxidized and reduced XOR, so its uric acid-lowering effect is more powerful and lasting. Therefore, this product can be used to treat chronic hyperuricemia in gout. On September 4, 2018, the domestic CFDA officially approved the listing of febuxostat. The domestic febuxostat is also called fibril.

Gout occurs due to excessive production of uric acid in the body and reduced kidney clearance ability. Uric acid accumulates in the body, leading to the deposition of urate crystals in joints and various organs. Therefore, gout is usually treated by promoting uric acid excretion and inhibiting uric acid production, and taking appropriate measures to improve related symptoms. The production of uric acid in the body is related to purine metabolism. In the final step of purine metabolism, hypoxanthine generates xanthine under the action of xanthine oxidoreductase (XOR), and then further generates uric acid. Inhibiting the activity of this enzyme can effectively reduce the production of uric acid.

Febuxostat is the latest XOR inhibitor developed in the world. It acts on this oxidase highly selectively, reducing the synthesis of uric acid in the body and lowering the concentration of uric acid, thereby effectively treating ventilation diseases. For 30 years, allopurinol has been the only clinical drug used to inhibit the production of uric acid. It has been widely used clinically as a gold treatment drug for gout and has achieved good results in the treatment of gout. Compared with allopurine, febuxostat has obvious advantages: allopurinol only inhibits the reduced form of XOR, while febuxostat has a significant inhibitory effect on both oxidized and reduced forms of XOR, so its uric acid-lowering effect is more powerful and lasting; because allopurinol is a purine analogue, it inevitably affects the activities of other enzymes involved in purine and pyridine metabolism. Therefore, repeated high-dose administration is required to maintain high drug levels during allopurinol treatment. This also leads to serious or even fatal adverse reactions due to drug accumulation. It is a non-purine XOR inhibitor and therefore has better safety profile.